Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
Feuerstein
G
G
Cardiovascular Pharmacology, Smith Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939, USA.
Ruffolo
R R
RR
D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D002227:Carbazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D000077261:Carvedilol; D002986:Clinical Trials as Topic; D016166:Free Radical Scavengers; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011412:Propanolamines / Q000494:pharmacology* / Q000627:therapeutic use*; D018342:Receptors, Adrenergic, beta-1 / Q000502:physiology; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology; D014665:Vasodilator Agents
D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D016166:Free Radical Scavengers; D011412:Propanolamines; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; D014665:Vasodilator Agents; D000077261:Carvedilol